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Letters to the Editor 
Dear Editor 
Effects of N-Acetylcysteine on hyperoxic lung in the 
rat 
It is becoming increasingly recognized that 
exposure to hyperoxia results in pulmonary injury, 
and this is closely related to oxidant-antioxidant 
imbalance in the lung. The main stay of the patho- 
physiology of this condition is the effect of oxygen- 
derived free radicals on the alveolocapillary barrier 
(ACB) (1). Studies have shown that N-acetylcysteine 
(NW, a thiol-containing compound, non- 
enzymatically interacts and detoxifies free radicals 
(2). We have investigated the effectiveness of NAC as 
a cytoprotective agent against hyperoxic pulmonary 
damage in experimental animals. Thirty wistar rats 
(weight 250 f 30 g) were used in these experiments 
and divided into three groups. The first group was 
exposed to 100% oxygen only; the second group 
was pre-treated with NAC 600 mg kg - ’ day ~ ’ for 
5 days, then exposed to 100% oxygen; the third group 
was also pre-treated with NAC as above but exposed 
to ambient air. Animals were killed 24 h later and 
their lungs were removed and examined by light 
microscopy (LM), and transmission electron micros- 
copy (TEM). Focal alveolar haemorrhage/oedema 
was assessed semi-quantitatively, while diffuse 
alveolar congestion and perivascular oedema was 
graded as slight, moderate or severe. 
Thirty-three percent of alveoli showed generalized 
congestion and slight perivascular oedema, in addi- 
tion to enlargement of the alveolar endothelium in 
all animals of the first group. In contrast, the alveoli 
of groups two and three appeared normal, but they 
were infiltrated by a large number of alveolar 
macrophages. 
These results suggest that NAC may act as an 
antioxidant, and reduce oxygen-derived free radicals 
which may increase permeability of ACB (3) and 
therefore reduce the inflammatory response mediated 
by neutrophils (4,5). 
We conclude that NAC can be utilized in the 
prevention of hyperoxic lung damage, as it reduces 
lung injury on ACB cells. 
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Dear Editor 
Home nebulizer service 
We were interested to read about the audit of 
a home nebulizer service provided by respiratory 
care nurse specialists from University Hospital, 
Nottingham. 
As a team of respiratory care nurses (3 full-time 
equivalents), we have been running an efficient 
nebulizer service for the past 5 yr, on much the same 
lines as described in the audit. We have had the 
benefit of a secretary to run the system administra- 
tively and have found that it works extremely well. 
The number of nebulizer compressors required has 
in fact dropped due to more efficient assessment and 
the finding that many patients benefit just as much 
from high dose bronchodilator by large volume 
spacer, as by nebulization. A local maintenance and 
repair service for nebulizers/compressors run by the 
hospital electronics engineering department with the 
co-operation of the manufacturers, has been running 
successfully for the past 2 yr. This is available to all 
patients who have had nebulizers provided by the 
unit, whether under continuing hospital follow-up 
or not. 
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